Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2016 call → NO我们根据提供的财报电话会议记录来判断。管理层是否描述了公司同类业务(如订单、合同等)的规模在逐步扩大?需要寻找管理层自己的表述,对比过去,且是当前现实,并表明这种扩大是近期发生的,未来还会继续。 在记录中,Josh Levine提到:“In the fourth quarter, greater than 50% of TomoTherapy orders were in single and dual vault settings, demonstrating the market's increasing recognition of the workhorse capabilities and industry-leading reliability of this product. TomoTherapy Systems are increasingly being placed outside of multi-bunker academic settings, which represents continued expansion of the selling opportunity we have with TomoTherapy.” 这说的是TomoTherapy订单更多出现在单/双vault设置,即非多bunker学术环境,这表示销售机会扩大,但并未明确说单个订单规模变大。 还有:“Additionally, we are also shifting resources to several key sustaining engineering projects...” 不相关。 关于多系统订单:“We have more -- we recorded more multi-system sales in the last fiscal year than any time in our history. It speaks to a lot of the work that we've done in regards to strategic accounts selling and positioning ourselves with larger groups and integrated delivery networks and health systems. And I expect that to continue.” 这里提到多系统销售比历史上任何时候都多,但这是指数量更多,还是单个订单更大?可能是指多系统订单的数量增加,但并未明确说每个订单的规模在逐步扩大。而且“more multi-system sales”可能是指更多笔多系统交易,而不是每笔交易更大。 还有关于NHS订单:“This was largest order in the company's history from a single customer and an important strategic win for us.” 但这是单个记录,管理层是否将其视为上升趋势的一部分?在回答中,Josh说:“It's important to note that we generated our record fourth quarter gross orders despite not recording a large domestic multi-system order that we referenced earlier and had expected close during our fiscal third quarter. The customer for that order has informed us that they now expect to place several individual orders in fiscal 2017 versus one large one, and in fact, the first of these systems has already gone into backlog in Q1 of the new fiscal year.” 这里提到一个大型国内多系统订单被拆分成几个单独订单,这实际上可能意味着单个订单规模变小了,而不是变大。 另外,关于Radixact和Onrad,都是新产品,但并未提及订单规模扩大。 管理层提到“multi-system orders”是重点,但并未明确说这些订单的规模在逐步增大。相反,有提到定价压力,但那是关于价格。 在回答分析师问题时,Josh说:“We have more -- we recorded more multi-system sales in the last fiscal year than any time in our history.” 这可能是说多系统销售的数量增加,但并未说每个订单的规模增加。而且“more”可能指数量。 此外,关于“backlog”增长8%,但那是总量。 因此,没有明确的管理层表述表明“同类业务的单位规模在逐步扩大”。相反,有提到大型订单被拆分,以及定价压力。所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.